In another strong week for IPOs, six companies combined to raise $1.2 billion. Five of the six realized positive first-day returns, and three finished their first day up more than 40%. This active week brought the total of 2017 IPOs to 106, passing the total for...read more
NuCana, a UK biotech developing second-generation chemotherapies for resistant tumors, raised $100 million by offering 6.7 million shares at $15, within the range of $14 to $16. NuCana plans to list on the Nasdaq under the symbol NCNA. Citi, Jefferies and...read more
NuCana, a UK biotech developing enhanced chemotherapies for resistant tumors, announced terms for its IPO on Monday. The Edinburgh, United Kingdom-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14 to $16. At...read more
US IPO Weekly Recap: Roku streams ahead in week of 6 IPOs
In another strong week for IPOs, six companies combined to raise $1.2 billion. Five of the six realized positive first-day returns, and three finished their first day up more than 40%. This active week brought the total of 2017 IPOs to 106, passing the total for...read more
Enhanced chemotherapy biotech NuCana prices $100 million IPO at $15 midpoint
NuCana, a UK biotech developing second-generation chemotherapies for resistant tumors, raised $100 million by offering 6.7 million shares at $15, within the range of $14 to $16. NuCana plans to list on the Nasdaq under the symbol NCNA. Citi, Jefferies and...read more
US IPO Week Ahead: Set-top boxes top off the 3Q17 as Roku headlines 7-IPO week
The IPO market will close out the third quarter with another active week: Seven deals are expected to raise $1.3 billion. High-growth TV streaming...read more
UK chemotherapy biotech NuCana sets terms for $100 million IPO
NuCana, a UK biotech developing enhanced chemotherapies for resistant tumors, announced terms for its IPO on Monday. The Edinburgh, United Kingdom-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14 to $16. At...read more